Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia

被引：3
|
作者：
Yusof, M. Md [1 ]
Cescon, D. W. [2 ]
Rugo, H. S. [3 ]
Im, S-A. [4 ]
Gallardo, C. [5 ]
Lipatov, O. [6 ]
Barrios, C. H. [7 ]
Holgado, E. [8 ,9 ,10 ]
Iwata, H. [11 ]
Masuda, N. [12 ]
Gokmen, E. [13 ]
Loi, S. [14 ]
Guo, Z. [15 ]
Jensen, E. [15 ]
Aktan, G. [16 ]
Karantza, V. [16 ]
Schmid, P. [17 ]
Cortes, J. [18 ,19 ,20 ,21 ]
机构：
[1] Pantai Hosp, Dept Oncol, Kuala Lumpur, Malaysia
[2] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Calif San Francisco, Dept Hematol Oncol, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[5] Arturo Lopez Perez Fdn, Inst Oncol, Santiago, Chile
[6] Republican Clin Oncol Dispensary, Dept Oncol, Republic Bashkortostan, Russia
[7] Pontificia Univ Catolica Rio Grande do Sul, HSL, Ctr Pesquisa Oncol, Dept Med, Porto Alegre, RS, Brazil
[8] IOB Inst Oncol, Quironsalud Grp, Breast Canc Program, Madrid, Spain
[9] IOB Inst Oncol, Quironsalud Grp, Breast Canc Program, Barcelona, Spain
[10] Ramon & Cajal Univ Hosp, Madrid, Spain
[11] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[12] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Breast Oncol, Osaka, Japan
[13] Ege Univ, Dept Med Oncol, Med Fac, Izmir, Turkey
[14] Peter MacCallum Canc Inst, Dept Res & Canc Med, Melbourne, Vic, Australia
[15] Merck & Co Inc, Biostat, Kenilworth, NJ USA
[16] Merck & Co Inc, Oncol, Kenilworth, NJ USA
[17] Barts Canc Inst, Centre Expt Canc Med, London, England
[18] IOB Inst Oncol, Breast Canc Program, Quironsalud Grp, Madrid, Spain
[19] IOB Inst Oncol, Breast Canc Program, Quironsalud Grp, Barcelona, Spain
[20] Vall dHebron Inst Oncol, Madrid, Spain
[21] Vall dHebron Inst Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
430
引用
收藏
页码：S1257 / S1257
页数：1
相关论文
共 50 条
  • [1] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (PBO) plus chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes Castan, J.
    Guo, Z.
    Karantza, V.
    Aktan, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (PBO) plus chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).
    Cortes, Javier
    Guo, Zifang
    Karantza, Vassiliki
    Aktan, Gursel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [3] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) 1 chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes Castan, J.
    Guo, Z.
    Karantza, V.
    Aktan, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer
    Rugo, Hope
    Schmid, Peter
    Nowecki, Zbigniew
    Cescon, David
    Im, Seock-Ah
    Yusof, Mastura
    Gallardo, Carlos
    Iwata, Hiroji
    Barrios, Carlos
    Loi, Sherene
    Zhou, Xuan
    Zhang, Xiaoli
    Pan, Wilbur
    Karantza, Vassiliki
    Cortes, Javier
    CANCER RESEARCH, 2024, 84 (09)
  • [5] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes, Javier
    Guo, Zifang
    Karantza, Vassiliki
    Aktan, Gursel
    CANCER RESEARCH, 2017, 77
  • [6] Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
    Cortes, Javier
    Cescon, David W.
    Rugo, Hope S.
    Nowecki, Zbigniew
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos Henrique
    Perez-Garcia, Jose
    Iwata, Hiroji
    Masuda, Norikazu
    Otero, Marco Torregroza
    Gokmen, Erhan
    Loi, Sherene
    Guo, Zifang
    Zhou, Xuan
    Karantza, Vassiliki
    Pan, Wilbur
    Schmid, Peter
    CANCER RESEARCH, 2022, 82 (04)
  • [7] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
    Schmid, P.
    Cortes, J.
    Dent, R.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Fasching, P. A.
    Cardoso, F.
    Jia, L.
    Karantza, V.
    Zhao, J.
    Aktan, G.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 853 - 854
  • [8] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
    Cortes, Javier
    Cescon, David W.
    Rugo, Hope S.
    Nowecki, Zbigniew
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos H.
    Holgado, Esther
    Iwata, Hiroji
    Masuda, Norikazu
    Torregroza Otero, Marco
    Gokmen, Erhan
    Loi, Sherene
    Guo, Zifang
    Zhao, Jing
    Aktan, Gursel
    Karantza, Vassiliki
    Schmid, Peter
    LANCET, 2020, 396 (10265): : 1817 - 1828
  • [9] KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
    Dent, R.
    Cortes, J.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Fasching, P. A.
    Cardoso, F.
    Jia, L.
    Jensen, E.
    Karantza, V.
    Aktan, G.
    O'Shaughnessy, J.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1241 - S1242
  • [10] KEYNOTE-355 Asian subset: Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for triple-negative breast cancer
    Takano, Toshimi
    Cortes, Javier
    Cescon, David W.
    Im, Seock-Ah
    Yusof, Mastura Md
    Iwata, Hiroji
    Masuda, Norikazu
    Huang, Chiun-Sheng
    Chung, Chi-Feng
    Tsugawa, Koichiro
    Park, Yeon Hee
    Matsumoto, Koji
    Inoue, Kenichi
    Kwong, Ava
    Loi, Sherene
    Fu, Wei
    Pan, Wilbur
    Karantza, Valia
    Rugo, Hope S.
    Schmid, Peter
    ANNALS OF ONCOLOGY, 2022, 33 : S465 - S465
12345